- What does FBTTX invest in?
- This fund primarily allocates its capital to common equities. A substantial portion, specifically at least 80% of its total assets, is dedicated to companies deeply involved in the biotechnology industry. This encompasses businesses engaged in the research, development, manufacturing, and distribution of biotechnological products, services, and processes, as well as those poised to benefit significantly from scientific and technological advancements in the field. Its investments span both domestic and international issuers. To select holdings, the fund employs a rigorous fundamental analysis, evaluating factors such as each company's financial strength, its competitive position within its industry, and broader market and economic conditions. It operates as a non-diversified fund.
- What is the expense ratio of FBTTX?
- Fidelity Advisor Biotechnology Fund (FBTTX) charges an expense ratio of 1.21%. This is the annual fee deducted from fund assets to cover management and operations.
- How big is FBTTX?
- Fidelity Advisor Biotechnology Fund (FBTTX) manages $2.28B in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.
- Is FBTTX actively managed or an index fund?
- FBTTX's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.
- When was FBTTX launched?
- Fidelity Advisor Biotechnology Fund (FBTTX) launched in December 2000 and is managed by Fidelity.
- How has FBTTX performed?
- FBTTX's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.
